NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its third quarter revenues rose 4 percent, driven by strength in the company's sample-to-answer molecular business.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $74.1 million, up from $71.2 million in the year-ago quarter, and short of the average Wall Street estimate for revenues of $74.4 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.